<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015070920588N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2015-11-12</date_registration>
      <primary_sponsor>Vce chancellor for research of Isfahan University of Medical Scienses</primary_sponsor>
      <public_title>Comparison of Phenylephrine and Ephedrine in the  treatment of hypotension</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Phenylephrine and Ephedrine in the  treatment of hypotension after spinal anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/18232</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hypotension.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group-1 :Will receive 50μg Phenylephrine(group P) intravenousely after observation of hypotension episode(grater than %20 of baseline blood pressure) and in non responsive cases ephedrine will be infused and repeated till achieving normal blood pressure. If bradycardia develops (Heart rate bellow 60 beat per minute) 0.5 mg Atropine IV will be infused. Intervention 2: Intervention group-2 :Will receive 5mg Ephedrine(group E) intravenousely after observation of hypotension episode(grater than %20 of baseline blood pressure) and in non responsive cases ephedrine will be infused and repeated till achieving normal blood pressure. If bradycardia develops (Heart rate bellow 60 beat per minute) 0.5 mg Atropine IV will be infused.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Darioush Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Depatment of Anesthesia and critical care, Alzahra University Hospital, Hezarjrib street, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 3362 5555</telephone>
        <email>dmoradi@med.mui.ac.irdrdmoradi@gmail.com</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Darioush Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Depatment of Anesthesia and critical care, Alzahra University Hospital, Hezarjrib street, Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 31 3362 5555</telephone>
        <email>dmoradi@med.mui.ac.irdrdmorsdi@gmail.com</email>
        <affiliation>Isfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>inclusion criteria: 110  patient with ASA physical status class I-II aged 40-65 years who are candidates of lower extremity orthopedic surgery. &#13;
Exclusion criteria:Any hypersensitivity reaction to vasopressore or local anesthetic drugs, systemic diseases like cardiovascular, liver, or renal diseases and pregnancy.</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>195.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypotension due to drugs</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group-1 :Will receive 50μg Phenylephrine(group P) intravenousely after observation of hypotension episode(grater than %20 of baseline blood pressure) and in non responsive cases ephedrine will be infused and repeated till achieving normal blood pressure. If bradycardia develops (Heart rate bellow 60 beat per minute) 0.5 mg Atropine IV will be infused.</i_keyword>
      <i_keyword>Intervention group-2 :Will receive 5mg Ephedrine(group E) intravenousely after observation of hypotension episode(grater than %20 of baseline blood pressure) and in non responsive cases ephedrine will be infused and repeated till achieving normal blood pressure. If bradycardia develops (Heart rate bellow 60 beat per minute) 0.5 mg Atropine IV will be infused.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic  blood pressure. Timepoint: 2, 4, 6, 8, 10, 14, 20 and 30 minutes after arrival of the patient to the recovery room. Method of measurement: Noninvasive Blood pressure monitoring system.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: 2, 4, 6, 8, 10, 14, 20 and 30 minutes after arrival of the patient to the recovery room. Method of measurement: Noninvasive Blood pressure monitoring system.</prim_outcome>
      <prim_outcome>Mean arterial blood pressure. Timepoint: 2, 4, 6, 8, 10, 14, 20 and 30 minutes after arrival of the patient to the recovery room. Method of measurement: Noninvasive Blood pressure monitoring system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart rate. Timepoint: 2 ،4   ،  6  ،  8  ،  10   ،  14    ،  20 and  30 minutes after arrival of the patient to the recovery room. Method of measurement: pulse oxymetery.</sec_outcome>
      <sec_outcome>Arterial blood oxygen saturation. Timepoint: 2 ،4   ،  6  ،  8  ،  10   ،  14    ،  20 and  30 minutes after arrival of the patient to the recovery room. Method of measurement: pulse oxymetery.</sec_outcome>
      <sec_outcome>Drug and non drug related complications. Timepoint: Any time during the study. Method of measurement: clinical evaluation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vce chancellor for research of Isfahan University of Medical Scienses</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-12-11</approval_date>
        <contact_name>Isfahan University of Medical Sciences</contact_name>
        <contact_address>Research Deputy, Isfahan university of medical sciences, Hezarjrib Street, Isfahan, Iran Isfahan  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
